• Home
  • Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.

Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.

Author List
Laura Ann Huppert, Hope S. Rugo, Lajos Pusztai, Rita A. Mukhtar, Amy Jo Chien, Christina Yau, Denise M. Wolf, Donald A. Berry, Laura van 't Veer, Douglas Yee, Angela DeMichele, Laura Esserman
Publication
Journal of Clinical Oncology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/425026061
Publication Year
2022
Publication Title
Laura Ann Huppert, Hope S. Rugo, Lajos Pusztai, Rita A. Mukhtar, Amy Jo Chien, Christina Yau, Denise M. Wolf, Donald A. Berry, Laura van 't Veer, Douglas Yee, Angela DeMichele, Laura Esserman. Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial. Journal of Clinical Oncology. 2022 Jun 1; 40(16_suppl):504-504.